Trump says US will have 'lowest prices in the world' as last pharma giant signs on

WASHINGTON, DC: President Donald Trump declared a major victory on prescription costs on Thursday, April 23, after Regeneron became the final major company to join the administration’s pricing initiative aimed at lowering medicine costs for Americans.

Trump said the agreement moved the country closer to delivering the “lowest prices in the world” by forcing pharmaceutical companies to match prices offered in other wealthy nations.

The White House announced that Regeneron is now the 17th leading manufacturer to sign onto Trump’s “most favored nation” model, a policy that ties US medication prices more closely to lower rates seen abroad.

With Regeneron’s participation, the administration says deals now cover companies representing roughly 86 percent of the branded prescription market.

Trump finalizes deal with Regeneron

Under the new arrangement, Regeneron said it will cut prices on current and future medications sold through Medicaid programs nationwide.

The company also agreed to slash the cost of its cholesterol medicine Praluent for direct buyers through the TrumpRx website.

According to the administration, Praluent’s listed price through the platform will drop from $537 to $225, a sharp reduction designed to showcase the direct-to-patient pricing model.

The White House framed the move as proof that pressure from Washington including tariffs and manufacturing incentives can force the pharmaceutical industry to lower costs voluntarily.

Trump said, “With this announcement, 17 of the world’s largest pharmaceutical companies representing 80% of the branded market have now agreed to sell the medicines to American patients at the lowest prices anywhere in the world. We’re going to have the lowest prices in the world.”

Trump has repeatedly argued that Americans have long subsidized cheaper medicine overseas while paying the highest prices at home.

Officials said every state Medicaid program would now gain access to preferred pricing on new Regeneron medicines, which they claim could generate hundreds of millions of dollars in savings over time.

The administration also said the agreement would stop foreign governments from benefiting from American pharmaceutical innovation while imposing price controls abroad.

Massive US investment pledge

The company also announced plans to invest $27 billion in American research, manufacturing and development by 2029.

That expansion includes more than doubling domestic production capacity for biologic medicines distributed in the US.

According to the White House, total pharmaceutical investment commitments secured during Trump’s current term now stand at $448 billion in 15 months.

Alongside the pricing announcement, Regeneron revealed that the FDA approved a gene therapy called Otarmeni for children with a rare inherited form of deafness.

The treatment targets an extremely uncommon genetic condition believed to affect only about 50 children annually in the United States.

Regeneron said the therapy would be provided to eligible US patients at no cost, a move Trump described as life-changing for families hoping their children could hear.